---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-102805"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:39:45.676624+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Metagenomi reports 12-month durable FVIII activity in preclinical hemophilia A study

## Summary
- All three NHPs showed durable FVIII activity at 12 months: 82%, 41%, and 9%.
- FVIII levels consistent from 3-6 month to 9-12 month time points; no significant decline.
- Liver biopsy showed gene integration in forward orientation at 0.7% to 2.9%.
- Treatment well tolerated with only moderate transient liver transaminase elevations.
- Program on track for IND filing in 2026; company declared MGX-001 as development candidate.

## SEC filing metadata
- accession: 0000950170-24-102805
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000095017024102805/0000950170-24-102805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000095017024102805/mgx-20240903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-102805
- JSON: https://secwatch.observer/filing/0000950170-24-102805.json
- Plain text: https://secwatch.observer/filing/0000950170-24-102805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.